TWST on XNAS, Health Care, Twist Bioscience Corporation, job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 28%, but shares fell 31% in a month while insiders sold $93.9M in 90 days.
BadFree cash flow was -$89M over the last 12 months
Good128 institutions opened new positions, 4.3 times a year earlier
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Twist Bioscience Corp provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. The core of its business is a proprietary platform that allows it to manufacture synthetic DNA by writing DNA on a silicon chip. The company operates as one reportable and operating segment, through which it develops, manufactures and sells DNA Synthesis and Protein Solutions and NGS Applications products and services. It has presence in Americas, EMEA, and APAC. Majority of revenue comes from Americas. Its products are Genes, Oligo Pools, NGS, Variant Libraries, Synthetic Controls, Antibody Discovery, and VDR Solutions.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $126.6M, net loss $20.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $126.6M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$126.6M
-$20.6M
30 Jun 2026
$118.4M
-$35.1M
31 Mar 2026
$110.7M
-$44.0M
31 Dec 2025
$103.7M
-$30.5M
30 Sep 2025
$99.0M
-$27.1M
30 Jun 2025
$96.1M
$20.4M
31 Mar 2025
$92.8M
-$39.3M
31 Dec 2024
$88.7M
-$31.6M
30 Sep 2024
$84.7M
-$34.7M
30 Jun 2024
$81.5M
-$85.6M
31 Mar 2024
$75.3M
-$45.5M
31 Dec 2023
$71.5M
-$43.0M
30 Sep 2023
$66.9M
-$46.2M
30 Jun 2023
$63.7M
-$57.4M
31 Mar 2023
$60.2M
-$59.2M
31 Dec 2022
$54.2M
-$41.8M
30 Sep 2022
$57.3M
-$51.1M
30 Jun 2022
$56.1M
-$60.5M
31 Mar 2022
$48.1M
-$60.7M
31 Dec 2021
$42.0M
-$45.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$459.4M
$376.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+22%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$130.2M
-$77.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.08
-$1.30
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
52.4%
50.7%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-30.4%
-36.2%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-28.3%
-20.6%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-19.1%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$89.0M
-$75.6M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$581.9M
$232.4M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$13.02
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
15.3
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
7.9
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$93.9M
bought $0, sold $93.9M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+29%
429 13F filers vs 332
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
77.6M shares held by 13F filers (30 Sep 2026) of 68.2M outstanding (11 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
14%
9.8M shares sold short (30 Oct 2026) of 68.2M outstanding (11 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.3
9.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-3.6%
10.2M shares sold short in the report before, 9.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
52%
52% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
56
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+35%
23 vs 17 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+28%
$126.6M vs $99.0M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+61%
$20.0M vs $12.4M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$246K
the 12 months before: -$1.5M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$82K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
45
45 articles in the last 7 days; its usual week has 8 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.6×
45 articles in the last 7 days; its usual week has 8.
Unusual now sharp changes in the last 90 days, compared with its own past
New institutional positions 128, 4.3× a year earlier
Price $103.32 on 20 Nov 2026, +296% over 12 months (12-month range $26.07 to $205.00)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $152.9M in the last 12 months (the 12 months before: -$10.7M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 22 published in the last 12 months, +29% on the 12 months before.Revenue per quarter. Revenue $126.6M in the latest quarter, +28% on a year earlier.Capital spending per quarter. Capital spending $20.0M in the latest quarter, +61% on a year earlier.Institutional holders (13F filers). 429 13F filers reported holding it in the latest 13F quarter, +91% on a year earlier.Federal obligations. Federal obligations: $166K published in the last 12 months, +128% on the 12 months before.Lobbying spend. Lobbying spend: $82K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 30 Sep 2021: $38.0M, +17% on a year earlier; public on 24 Nov 2021
Quarter ended 31 Dec 2021: $42.0M, +49% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $48.1M, +54% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $56.1M, +60% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $57.3M, +51% on a year earlier; public on 29 Nov 2022
Quarter ended 31 Dec 2022: $54.2M, +29% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $60.2M, +25% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $63.7M, +14% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $66.9M, +17% on a year earlier; public on 22 Nov 2023
Quarter ended 31 Dec 2023: $71.5M, +32% on a year earlier; public on 3 Feb 2024
Quarter ended 31 Mar 2024: $75.3M, +25% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $81.5M, +28% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $84.7M, +27% on a year earlier; public on 19 Nov 2024
Quarter ended 31 Dec 2024: $88.7M, +24% on a year earlier; public on 4 Feb 2025
Quarter ended 31 Mar 2025: $92.8M, +23% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $96.1M, +18% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $99.0M, +17% on a year earlier; public on 18 Nov 2025
Quarter ended 31 Dec 2025: $103.7M, +17% on a year earlier; public on 3 Feb 2026
Quarter ended 31 Mar 2026: $110.7M, +19% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $118.4M, +23% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $126.6M, +28% on a year earlier; public on 17 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2021: $8.1M, +264% on a year earlier; public on 24 Nov 2021
Quarter ended 31 Dec 2021: $12.8M, +252% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $32.0M, +281% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $40.6M, +485% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $16.5M, +104% on a year earlier; public on 29 Nov 2022
Quarter ended 31 Dec 2022: $11.8M, -7.5% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $9.1M, -72% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $4.5M, -89% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $2.4M, -85% on a year earlier; public on 22 Nov 2023
Quarter ended 31 Dec 2023: $1.5M, -87% on a year earlier; public on 3 Feb 2024
Quarter ended 31 Mar 2024: $603K, -93% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $965K, -79% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $2.0M, -16% on a year earlier; public on 19 Nov 2024
Quarter ended 31 Dec 2024: $2.3M, +51% on a year earlier; public on 4 Feb 2025
Quarter ended 31 Mar 2025: $4.1M, +587% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $9.2M, +850% on a year earlier; public on 5 Aug 2025
Quarter ended 30 Sep 2025: $12.4M, +521% on a year earlier; public on 18 Nov 2025
Quarter ended 31 Dec 2025: $10.0M, +340% on a year earlier; public on 3 Feb 2026
Quarter ended 31 Mar 2026: $7.9M, +90% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $9.8M, +6.5% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $20.0M, +61% on a year earlier; public on 17 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 214; public on 14 Feb 2022
31 Mar 2022 report: 198; public on 16 May 2022
30 Jun 2022 report: 188; public on 15 Aug 2022
30 Sep 2022 report: 200; public on 14 Nov 2022
31 Dec 2022 report: 178; public on 14 Feb 2023
31 Mar 2023 report: 188; public on 15 May 2023
30 Jun 2023 report: 180; public on 14 Aug 2023
30 Sep 2023 report: 181; public on 14 Nov 2023
31 Dec 2023 report: 203; public on 14 Feb 2024
31 Mar 2024 report: 225; public on 15 May 2024
30 Jun 2024 report: 253; public on 14 Aug 2024
30 Sep 2024 report: 233; public on 14 Nov 2024
31 Dec 2024 report: 244; public on 14 Feb 2025
31 Mar 2025 report: 250; public on 15 May 2025
30 Jun 2025 report: 231; public on 14 Aug 2025
30 Sep 2025 report: 225; public on 14 Nov 2025
31 Dec 2025 report: 234; public on 17 Feb 2026
31 Mar 2026 report: 272; public on 15 May 2026
30 Jun 2026 report: 332; public on 14 Aug 2026
30 Sep 2026 report: 429; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $4.1M published
Month from 1 Jan 2022: $0 published
Month from 1 Feb 2022: $12K published
Month from 1 Mar 2022: $14K published
Month from 1 Apr 2022: -$54.2 published
Month from 1 May 2022: $26K published
Month from 1 Sep 2022: $75K published
Month from 1 Nov 2022: $0 published
Month from 1 Mar 2023: -$2K published
Month from 1 Apr 2023: $0 published
Month from 1 May 2023: $18K published
Month from 1 Jul 2023: $78K published
Month from 1 Aug 2023: $66K published
Month from 1 Oct 2023: $48K published
Month from 1 Dec 2023: -$2.9 published
Month from 1 Feb 2024: $24K published
Month from 1 May 2024: -$100K published
Month from 1 Jul 2024: $174K published
Month from 1 Aug 2024: $233K published
Month from 1 Sep 2024: $20K published
Month from 1 Nov 2024: -$1.8M published
Month from 1 Jun 2025: $12K published
Month from 1 Aug 2025: $61K published
Month from 1 Jun 2026: $47K published
Month from 1 Jul 2026: $97K published
Month from 1 Aug 2026: $17K published
Month from 1 Sep 2026: $5K published
Lobbying spend
Quarter from 1 Oct 2026: $82K published
What is unusual now
Made public in the last 90 days: it saw 128 13F filers open a new position in the quarter ended 30 Sep 2026, 4.3× the same quarter last year.
Many funds opening a new position: saw 128 13F filers open a new position in the quarter ended 30 Sep 2026, 4.3× the same quarter last year Public on 16 Nov 2026.
Department of DefenseDefense Advanced Research Projects Agency
LIVING FOUNDRIES: 1000 MOLECULES TA1. DARPA'S LIVING FOUNDRIES: 1000 MOLECULES PROGRAM SEEKS TO BUILD A SCALABLE, INTEGRATED, RAPID DESIGN AND PROTOTYPING INFRASTRUCTURE FOR THE FACILE ENGINEERING OF BIOLOGY. THIS EFFORT IS AN ADVANCED STUDY. THE TWIST EFFORT PROPOSES TO DEVELOP A LARGE SCALE, HIGH-THROUGHPUT PLATFORM FOR CONSTRUCTING LOW-COST GENETIC DESIGNS.
56 open postings; careers site tracked since 20 Nov 2026. Most in Manufacturing & production 20%, Sales & business development 16%, Research & science 12%, Marketing & communications 11%.
Reported lobbying spend: $82K in Q3 2026, $31K in Q2 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jun 2020
Ended
Erin Smith/ Smith Capitol Strategiesfor Twist Bioscience
Supporting the bioeconomy COVID-19 synthetic biology policy H.R.4373 - Engineering Biology Research and Development Act of 2019 S. 3734 Bioeconomy Development Act of 2020 Biosecurity standards American competitiveness; H.R.2740 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020/ Senate: No bill numberScience/technology, Budget
Two or more unrelated kinds of records unusual within 30 days
3 Feb 2026confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Twist Bioscience(TWST): had 14.3M shares sold short in the 31 Dec 2025 report, 1.6× the same report last year, while it spent $10.0M on capital projects in the quarter ended 31 Dec 2025, 4.4× the same quarter last year. Two unrelated kinds of activity within 21 days.
Short interest and volume: Short interest spike, became public on 13 Jan 2026
Financials: Quarterly capital spending jump, became public on 3 Feb 2026
The 31 Dec 2025 report against the 24 reports before it.
this reportearliernormal: 10.5MSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 13 Jan 2026
Twist Bioscience had 14.3M shares sold short in the 31 Dec 2025 report, 1.6× the same report last year.
This period
14.3M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.5M
Typical spread (median absolute deviation)
654K
How far from its usual level
+3.6
Same report last year
8.7M
History used
2,603 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 3 Feb 2026
Twist Bioscience spent $10.0M on capital projects in the quarter ended 31 Dec 2025, 4.4× the same quarter last year.
This period
$10.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$2.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+3.9
Same quarter last year
$2.3M
History used
2,922 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $2.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Feb 2022confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Twist Bioscience(TWST): spent $32.0M on capital projects in the quarter ended 31 Mar 2022, 3.8× the same quarter last year, while it had 8.3M shares sold short in the 13 May 2022 report, 2.1× the same report last year. Two unrelated kinds of activity within 119 days.
Short interest and volume: Short interest spike, became public on 27 Jan 2022
Financials: Quarterly capital spending jump, became public on 15 Feb 2022
Short interest and volume: Short interest spike, became public on 10 Feb 2022
Short interest and volume: Short interest spike, became public on 26 Feb 2022
Short interest and volume: Short interest spike, became public on 10 Mar 2022
Short interest and volume: Short interest spike, became public on 25 Mar 2022
Short interest and volume: Short interest spike, became public on 12 Apr 2022
Short interest and volume: Short interest spike, became public on 27 Apr 2022
Financials: Quarterly capital spending jump, became public on 10 May 2022
Short interest and volume: Short interest spike, became public on 11 May 2022
Short interest and volume: Short interest spike, became public on 25 May 2022
The quarter ended 31 Mar 2022 against the 8 quarters before it.
this quarterearliernormal: $5.3MSee the evidence (11 changes)
Short interest and volume: Short interest spike became public on 27 Jan 2022
Twist Bioscience had 5.0M shares sold short in the 14 Jan 2022 report, 2.1× the same report last year.
This period
5.0M (the 14 Jan 2022 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
278K
How far from its usual level
+3.8
Same report last year
2.4M
History used
1,156 days
the 14 Jan 2022 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 15 Feb 2022
Twist Bioscience spent $12.8M on capital projects in the quarter ended 31 Dec 2021, 3.5× the same quarter last year.
This period
$12.8M (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$3.2M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+5.9
Same quarter last year
$3.6M
History used
1,461 days
the quarter ended 31 Dec 20218 earlier quartersnormal: $3.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Feb 2022
Twist Bioscience had 5.4M shares sold short in the 31 Jan 2022 report, 3.0× the same report last year.
This period
5.4M (the 31 Jan 2022 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
279K
How far from its usual level
+4.9
Same report last year
1.8M
History used
1,173 days
the 31 Jan 2022 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2022
Twist Bioscience had 5.4M shares sold short in the 15 Feb 2022 report, 2.7× the same report last year.
This period
5.4M (the 15 Feb 2022 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
298K
How far from its usual level
+4.4
Same report last year
2.0M
History used
1,188 days
the 15 Feb 2022 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Mar 2022
Twist Bioscience had 6.0M shares sold short in the 28 Feb 2022 report, 2.3× the same report last year.
This period
6.0M (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
331K
How far from its usual level
+4.9
Same report last year
2.6M
History used
1,201 days
the 28 Feb 2022 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2022
Twist Bioscience had 6.1M shares sold short in the 15 Mar 2022 report, 1.7× the same report last year.
This period
6.1M (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
344K
How far from its usual level
+5.0
Same report last year
3.6M
History used
1,216 days
the 15 Mar 2022 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Apr 2022
Twist Bioscience had 6.4M shares sold short in the 31 Mar 2022 report, 1.6× the same report last year.
This period
6.4M (the 31 Mar 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
345K
How far from its usual level
+5.4
Same report last year
4.1M
History used
1,232 days
the 31 Mar 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Apr 2022
Twist Bioscience had 6.7M shares sold short in the 14 Apr 2022 report, 1.8× the same report last year.
This period
6.7M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
375K
How far from its usual level
+5.5
Same report last year
3.8M
History used
1,246 days
the 14 Apr 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 10 May 2022
Twist Bioscience spent $32.0M on capital projects in the quarter ended 31 Mar 2022, 3.8× the same quarter last year.
This period
$32.0M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$5.3M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+6.7
Same quarter last year
$8.4M
History used
1,551 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $5.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 11 May 2022
Twist Bioscience had 7.3M shares sold short in the 29 Apr 2022 report, 2.1× the same report last year.
This period
7.3M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
390K
How far from its usual level
+6.3
Same report last year
3.5M
History used
1,261 days
the 29 Apr 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 May 2022
Twist Bioscience had 8.3M shares sold short in the 13 May 2022 report, 2.1× the same report last year.
This period
8.3M (the 13 May 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
479K
How far from its usual level
+6.5
Same report last year
4.0M
History used
1,275 days
the 13 May 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
30 Nov 2021confirmed
Confirmed across sources Government contracts and Filings + Financials and Short interest and volume
Twist Bioscience(TWST): won its first award from the Department of Health and Human Services, a $2.7M contract, after 1 earlier federal award from other agencies; it also spent $8.1M on capital projects in the quarter ended 30 Sep 2021, 3.6× the same quarter last year; and it had 4.9M shares sold short in the 15 Dec 2021 report, 1.7× the same report last year. Three unrelated kinds of activity within 42 days.
Government contracts: First award from a new federal agency, became public on 16 Nov 2021
Financials: Quarterly capital spending jump, became public on 30 Nov 2021
Short interest and volume: Short interest spike, became public on 28 Dec 2021
The quarter ended 30 Sep 2021 against the 8 quarters before it.
this quarterearliernormal: $3.2MSee the evidence (3 changes)
Government contracts: First award from a new federal agency became public on 16 Nov 2021
Twist Bioscience won its first award from the Department of Health and Human Services, a $2.7M contract, after 1 earlier federal award from other agencies.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Financials: Quarterly capital spending jump became public on 30 Nov 2021
Twist Bioscience spent $8.1M on capital projects in the quarter ended 30 Sep 2021, 3.6× the same quarter last year.
This period
$8.1M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$3.2M
Typical spread (median absolute deviation)
$834K
How far from its usual level
+3.9
Same quarter last year
$2.2M
History used
1,369 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $3.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 28 Dec 2021
Twist Bioscience had 4.9M shares sold short in the 15 Dec 2021 report, 1.7× the same report last year.
This period
4.9M (the 15 Dec 2021 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
286K
How far from its usual level
+3.6
Same report last year
2.9M
History used
1,126 days
the 15 Dec 2021 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
16 Nov 2026Institutional holdings change
saw 128 13F filers open a new position in the quarter ended 30 Sep 2026, 4.3× the same quarter last year.
Same quarter last year: 30; its normal quarter is 35.
See the evidence
This period
128 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
35
Typical spread (median absolute deviation)
7.5
How far from its usual level
+8.4
Same quarter last year
30
History used
2,830 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 35
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 14.3M shares sold short in the 31 Dec 2025 report, 1.6× the same report last year, while it spent $10.0M on capital projects in the quarter ended 31 Dec 2025, 4.4× the same quarter last year. Two unrelated kinds of activity within 21 days.
See the evidence (2 changes)
Short interest and volume: Short interest spike became public on 13 Jan 2026
Twist Bioscience had 14.3M shares sold short in the 31 Dec 2025 report, 1.6× the same report last year.
This period
14.3M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.5M
Typical spread (median absolute deviation)
654K
How far from its usual level
+3.6
Same report last year
8.7M
History used
2,603 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 3 Feb 2026
Twist Bioscience spent $10.0M on capital projects in the quarter ended 31 Dec 2025, 4.4× the same quarter last year.
This period
$10.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$2.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+3.9
Same quarter last year
$2.3M
History used
2,922 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $2.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
3 Feb 2026Financials change
spent $10.0M on capital projects in the quarter ended 31 Dec 2025, 4.4× the same quarter last year.
Same quarter last year: $2.3M; its normal quarter is $2.1M.
See the evidence
This period
$10.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$2.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+3.9
Same quarter last year
$2.3M
History used
2,922 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $2.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 14.3M shares sold short in the 31 Dec 2025 report, 1.6× the same report last year.
Same report last year: 8.7M; its normal report is 10.5M.
See the evidence
This period
14.3M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.5M
Typical spread (median absolute deviation)
654K
How far from its usual level
+3.6
Same report last year
8.7M
History used
2,603 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $12.4M on capital projects in the quarter ended 30 Sep 2025, 6.2× the same quarter last year.
Same quarter last year: $2.0M; its normal quarter is $2.1M.
See the evidence
This period
$12.4M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$2.1M
Typical spread (median absolute deviation)
$900K
How far from its usual level
+7.7
Same quarter last year
$2.0M
History used
2,830 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $2.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $9.2M on capital projects in the quarter ended 30 Jun 2025, 9.5× the same quarter last year.
Same quarter last year: $965K; its normal quarter is $2.1M.
See the evidence
This period
$9.2M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$2.1M
Typical spread (median absolute deviation)
$900K
How far from its usual level
+5.3
Same quarter last year
$965K
History used
2,738 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $2.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 12.1M shares sold short in the 14 Apr 2023 report, 1.8× the same report last year.
Same report last year: 6.7M; its normal report is 6.7M.
See the evidence
This period
12.1M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
993K
How far from its usual level
+3.7
Same report last year
6.7M
History used
1,611 days
the 14 Apr 2023 report24 earlier reportsnormal: 6.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.9M shares sold short in the 31 Mar 2023 report, 1.9× the same report last year.
Same report last year: 6.4M; its normal report is 6.5M.
See the evidence
This period
11.9M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
786K
How far from its usual level
+4.6
Same report last year
6.4M
History used
1,597 days
the 31 Mar 2023 report24 earlier reportsnormal: 6.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.1M shares sold short in the 15 Mar 2023 report, 1.8× the same report last year.
Same report last year: 6.1M; its normal report is 6.4M.
See the evidence
This period
11.1M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
539K
How far from its usual level
+5.8
Same report last year
6.1M
History used
1,581 days
the 15 Mar 2023 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.0M shares sold short in the 28 Feb 2023 report, 1.7× the same report last year.
Same report last year: 6.0M; its normal report is 6.3M.
See the evidence
This period
10.0M (the 28 Feb 2023 report)
Normal report (median of 24 earlier)
6.3M
Typical spread (median absolute deviation)
390K
How far from its usual level
+5.8
Same report last year
6.0M
History used
1,566 days
the 28 Feb 2023 report24 earlier reportsnormal: 6.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.4M shares sold short in the 15 Feb 2023 report, 1.7× the same report last year.
Same report last year: 5.4M; its normal report is 6.3M.
See the evidence
This period
9.4M (the 15 Feb 2023 report)
Normal report (median of 24 earlier)
6.3M
Typical spread (median absolute deviation)
446K
How far from its usual level
+4.8
Same report last year
5.4M
History used
1,553 days
the 15 Feb 2023 report24 earlier reportsnormal: 6.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.2M shares sold short in the 31 Jan 2023 report, 1.7× the same report last year.
Same report last year: 5.4M; its normal report is 6.2M.
See the evidence
This period
9.2M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
6.2M
Typical spread (median absolute deviation)
461K
How far from its usual level
+4.3
Same report last year
5.4M
History used
1,538 days
the 31 Jan 2023 report24 earlier reportsnormal: 6.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.1M shares sold short in the 13 Jan 2023 report, 1.8× the same report last year.
Same report last year: 5.0M; its normal report is 6.2M.
See the evidence
This period
9.1M (the 13 Jan 2023 report)
Normal report (median of 24 earlier)
6.2M
Typical spread (median absolute deviation)
461K
How far from its usual level
+4.3
Same report last year
5.0M
History used
1,520 days
the 13 Jan 2023 report24 earlier reportsnormal: 6.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.7M shares sold short in the 30 Dec 2022 report, 1.8× the same report last year.
Same report last year: 4.9M; its normal report is 6.1M.
See the evidence
This period
8.7M (the 30 Dec 2022 report)
Normal report (median of 24 earlier)
6.1M
Typical spread (median absolute deviation)
416K
How far from its usual level
+4.2
Same report last year
4.9M
History used
1,506 days
the 30 Dec 2022 report24 earlier reportsnormal: 6.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $56.1M for the quarter ended 30 Jun 2022, 1.6× the same quarter last year.
Same quarter last year: $35.0M; its normal quarter is $33.7M.
See the evidence
This period
$56.1M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$33.7M
Typical spread (median absolute deviation)
$4.9M
How far from its usual level
+3.1
Same quarter last year
$35.0M
History used
1,642 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $33.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
spent $40.6M on capital projects in the quarter ended 30 Jun 2022, 5.9× the same quarter last year.
Same quarter last year: $6.9M; its normal quarter is $7.5M.
See the evidence
This period
$40.6M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$7.5M
Typical spread (median absolute deviation)
$4.3M
How far from its usual level
+5.2
Same quarter last year
$6.9M
History used
1,642 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $7.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 8.3M shares sold short in the 13 May 2022 report, 2.1× the same report last year.
Same report last year: 4.0M; its normal report is 3.7M.
See the evidence
This period
8.3M (the 13 May 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
479K
How far from its usual level
+6.5
Same report last year
4.0M
History used
1,275 days
the 13 May 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.3M shares sold short in the 29 Apr 2022 report, 2.1× the same report last year.
Same report last year: 3.5M; its normal report is 3.7M.
See the evidence
This period
7.3M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
390K
How far from its usual level
+6.3
Same report last year
3.5M
History used
1,261 days
the 29 Apr 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $32.0M on capital projects in the quarter ended 31 Mar 2022, 3.8× the same quarter last year.
Same quarter last year: $8.4M; its normal quarter is $5.3M.
See the evidence
This period
$32.0M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$5.3M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+6.7
Same quarter last year
$8.4M
History used
1,551 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $5.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 6.7M shares sold short in the 14 Apr 2022 report, 1.8× the same report last year.
Same report last year: 3.8M; its normal report is 3.7M.
See the evidence
This period
6.7M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
375K
How far from its usual level
+5.5
Same report last year
3.8M
History used
1,246 days
the 14 Apr 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.4M shares sold short in the 31 Mar 2022 report, 1.6× the same report last year.
Same report last year: 4.1M; its normal report is 3.7M.
See the evidence
This period
6.4M (the 31 Mar 2022 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
345K
How far from its usual level
+5.4
Same report last year
4.1M
History used
1,232 days
the 31 Mar 2022 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 84 entries; narrow the window or the kind of data to see older ones.
Not listed: 607 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001581280
Ticker
TWST
Domain
twistbioscience.com
Employer name
Twist Bioscience Corporation (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
twist bioscience
Name
2.Twist Bio Computing, LLC, a Delaware limited liability company, 3.Twist Pharmaceutical Solutions, LLC, a Delaware limited liability company, 5.iGenomX International Genomics, LLC, a Delaware limited liability company, 7.AbX Biologics, Inc., a Delaware corporation and 7 more
Uei
CMN5DM38JLN1
Wikidata
Q43303430
Wikipedia
Twist Bioscience
DOL H-1B labor condition applications and PERM certifications425 data points2 Mar 2020 to 28 Sep 2026
Federal lobbying disclosures (LDA)3 records, 26 data points16 Sep 2019 to 30 Sep 2026
SEC Form 13F institutional holdings288 data points31 Dec 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)105 records19 Jan 2016 to 16 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)673 data points30 Sep 2016 to 11 Nov 2026
SEC Form 4 insider transactions533 records, 1136 data points6 Nov 2018 to 18 Nov 2026
FINRA short interest (twice monthly)572 data points15 Nov 2018 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4050 data points31 Oct 2018 to 20 Nov 2026
USASpending.gov federal awards2 records, 183 data points30 Apr 2014 to 26 Aug 2026
Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026